Grifols SA (GRFS) Company Overview

Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9%

On January 14, 2025, Grifols, a global healthcare company known for producing plasma-derived medicines, announced that it has received funding from The Michael J. Fox Foundation for Parkinson's Research. This grant will support a project named "Chronos-PD," which aims to find plasma-based biomarkers that may predict a person's risk of developing Parkinson's disease long before it is clinically diagnosed. The project could help speed up the creation of new diagnostic methods and innovative treatments for the disease.

Mason Capital, an investment fund based in the U.S., announced on Monday that it has written to Spain's stock market regulator, CNMV, asking for greater transparency from the troubled pharmaceutical company Grifols.

Mason Capital Management LLC, an investment advisor managing about 2.5% of Grifols S.A. shares, has reached out to the Spanish National Securities Market Commission (CNMV). They expressed concerns about the lack of transparency from Grifols and its Board of Directors, which they believe is harmful to the company's value. In their letter, Mason is urging the CNMV to take action on this issue.

Mason Capital Management LLC, which manages funds holding about 2.1% of Grifols S.A. shares, has reached out to the Grifols Board of Directors. They are asking for the release of key information about Tomas Daga, who has been on the Board for nearly 25 years and is a close advisor to the Grifols family. This request aims to provide shareholders with more clarity.

MADRID--(BUSINESS WIRE)--The law firm Araoz y Rueda has been hired by various international and Spanish organizations (the “Clients”) that together own 5.65% of A shares and 3.88% of B shares (including ADRs) in Grifols, S.A. As of the closing prices on 29 November 2024, the total value of the Clients' investment in Grifols is €275 million. The Clients express their gratitude to the Transaction Committee for their full commitment to Brookfield and strongly back the decision.

On Wednesday, Grifols SA GRFS announced that it has stopped talks with Brookfield Capital Partners (UK) Limited regarding a possible acquisition.

I only sell my investments if the main reasons for buying them change. I think Brookfield Asset Management's buyout offer for Grifols is too low, so I still recommend buying the stock. The recent 3Q24 results and the transaction committee's advice against accepting the €10.5 per share offer support my belief that Grifols is worth more.

Brookfield has chosen to withdraw its buyout proposal for GRFS due to differences in the company's valuation.